Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. March 20, 2018. Raul Nogueira.

Executive Summary

Check out what Raul Nogueira, the principal investigator of the DAWN acute stroke clinical trial, had to say about the new paradigm for treating strokes that should result from the study data, which device-maker Stryker is getting out ahead of.

"It's more than opening up the window from six to 24 hours; it's also another way of thinking about stroke. It's more physiology-based rather than time-based." –Raul Nogueira, neuroendovascular division director, Grady Memorial Hospital

Click here for a free trial of Medtech Insight


Related Content

Stryker Pushes For Changes To Stroke Care After DAWN





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts